You are here

Database of section 19A approvals to import and supply medicines to address medicine shortages

Database of section 19A approvals to import and supply medicines during a shortage

15 January 2019

This database provides information on medicines not on the Australian Register of Therapeutic Goods (ARTG) that are approved for import and supply in Australia because:

  • there is a shortage of a medicine registered in Australia; and
  • the medicine is needed in the interest of public health.

The database holds information on approvals current on or after 21 Feburary 2018. Contact the TGA's Medicines Shortages Section for information on approvals that expired or lapsed before 21 Feburary 2018.

Consumers can use medicines accessed under section 19A until the medicines expire.

The 'Import and supply approved until' date applies to the approval holder importing and supplying the medicine.

The Medicines Shortages Information Initiative lists medicines that are unavailable or in short supply. If you are having difficulty obtaining a treatment that has been prescribed to you, talk to your doctor or pharmacist.

Section 19A approvals are granted for a specified period, which usually coincides with the period that the medicine on the ARTG is unavailable or in short supply. However, approval may lapse early if:

  • a decision has been made about whether or not to register the medicine in Australia
  • any of the specific criteria for approval no longer apply (for example, the registered medicine is no longer in short supply)
  • a condition of approval has been breached.

Section 19A approvals are subject to a number of conditions specified by the TGA including the following (though additional conditions can be imposed where the circumstances warrant it):

  • the approval applies only to the medicine specified in the approval
  • the approval is only for importation into and supply within Australia
  • the medicine is sourced from manufacturers with acceptable evidence of Good Manufacturing Practice (GMP)
  • a letter to health professionals who will be prescribing the medicine is usually required
  • the goods must be labelled with the name and address of the approval holder to ensure that adverse events can be reported.
Open all | Close all
If you want to print all details, you need to Open all before you print.

Section 19A approvals

Displaying 1 - 10 of 77

Enter a approval holder, product name, active ingredient, indication or ARTG number.

Section 19A approved medicine:

CARBIDOPA and LEVODOPA TABLETS, USP 25mg/250mg carbidopa/levodopa tablet bottle

Import and supply approved until: 30 April 2019

Medicine in short supply/unavailable:

  • SINEMET 250/25 levodopa/carbidopa 250mg/25mg tablet bottle - ARTG 171666

Section 19A approval holder:

Medsurge Healthcare Pty Ltd ABN 92 124 728 892

Approval holder phone number: 1300 788 261

  • Indicated for the treatment of Parkinson's disease and syndrome. It is useful in relieving many of the symptoms of parkinsonism, particularly rigidity and bradykinesia.

  • Frequently helpful in the management of tremor, dysphagia, sialorrhoea and postural instability associated with Parkinson's disease and syndrome.
  • Section 19A approved medicine:

    ADRENALINE RENAUDIN adrenaline 1 mg/mL solution for injection, 1mL ampoule

    Import and supply approved until: 15 May 2019

    Medicine in short supply/unavailable:

    • ADRENALINE-LINK 1:1,000 1mg/1mL adrenaline (epinephrine) acid tartrate injection BP ampoule - ARTG 12048

    Section 19A approval holder:

    Link Medical Products Pty Ltd ABN 73 010 971 516

    Approval holder phone number: 1800 181 060

    For the treatment of anaphylactic shock.

    Section 19A approved medicine:

    Pantoprazole Sodium for Injection, 40mg per vial

    Import and supply approved until: 31 March 2019

    Medicine in short supply/unavailable:

    • PANTOPRAZOLE SANDOZ pantoprazole (as sodium) 40mg powder for injection vial - ARTG 147377
    • PANTOPRAZOLE SUN pantoprazole (as sodium) 40mg powder for injection vial - ARTG 172172

    Section 19A approval holder:

    Medsurge Healthcare Pty Ltd ABN 92 124 728 892

    Approval holder phone number: 1300 788 261

    For short-term use where oral therapy is not appropriate for the following conditions:

  • Symptomatic improvement and healing of gastrointestinal diseases which require a reduction in acid secretion, e.g. duodenal ulcer, gastric ulcer, reflux oesophagitis, gastrointestinal lesions refractory to H2 blockers, Zollinger-Ellison Syndrome.

  • Maintenance of healed reflux oesophagitis in patients previously treated for moderate to severe reflux oesophagitis.

    Note: Patients whose gastric or duodenal ulceration is not associated with ingestion of nonsteroidal anti-inflammatory drugs require treatment with antimicrobial agents in addition to antisecretory medicines, whether on first presentation or recurrence

  • Section 19A approved medicine:

    (Approval lapsed 11 December 2018) Nifedipine AL 10 (10 mg immediate-release nifedipine) capsules

    Import and supply approved until: 1 January 2020

    Medicine in short supply/unavailable:

    • ADALAT 10 nifedipine 10mg tablet blister pack - ARTG43103
    • ADEFIN 10 nifedipine 10mg tablet blister pack - ARTG 92999

    Section 19A approval holder:

    Medsurge Healthcare Pty Ltd ABN 92 124 728 892

    Approval holder phone number: 1300 788 261

  • Chronic stable angina pectoris (angina)

  • Vasospastic angina (Prinzmetal's angina, variant angina)

  • Essential hypertension
  • Section 19A approved medicine:

    (Approval lapsed 11 December 2018) Nifedipine AL T 20 Retard (20 mg modified-release nifedipine) tablets

    Import and supply approved until: 19 April 2019

    Medicine in short supply/unavailable:

    • ADALAT OROS nifedipine 20mg tablet blister pack - ARTG 60101

    Section 19A approval holder:

    Medsurge Healthcare Pty Ltd ABN 92 124 728 892

    Approval holder phone number: 1300 788 261

  • Chronic stable angina pectoris (angina)

  • Vasospastic angina (Prinzmetal's angina, variant angina)

  • Essential hypertension
  • Section 19A approved medicine:

    MINIMS Pilocarpine nitrate 2% w/v Eye Drops

    Import and supply approved until: 28 February 2019

    Medicine in short supply/unavailable:

    • MINIMS PILOCARPINE NITRATE 2% 20mg/mL eye drops tube - ARTG 32280

    Section 19A approval holder:

    Bausch & Lomb Australia Pty Ltd ABN 88 000 222 408

    Approval holder phone number: 1800 251 150

    Pilocarpine is used as a miotic, for reversing the action of weaker mydriatics and in the emergency treatment of glaucoma.

    Section 19A approved medicine:

    BCG-medac, powder and solvent for suspension for intravesical use

    Import and supply approved until: 31 January 2020

    Medicine in short supply/unavailable:

    • ONCOTICE BCG 5 hundred million CFU powder for injection vial - ARTG 59912

    Section 19A approval holder:

    Link Medical Products Pty Ltd ABN 73 010 971 516

    Approval holder phone number: 1800 181 060

    Treatment of primary or recurrent carcinoma in situ (CIS) of the urinary bladder. Intravesical BCG is also used after transurethral resection for the prevention of recurrence of high grade and/or relapsing superficial papillary transitional cell carcinoma of the urinary bladder (viz papillary carcinoma stage TA [grade 2 or 3] or T1 [grade 1, 2, or 3]). Intravesical BCG is only recommended for stage TA grade 1 tumours, when there is judged to be a high risk of tumour recurrence.

    Section 19A approved medicine:

    Yaltormin SR 500mg (metformin hydrochloride) Prolonged Release Tablets

    Import and supply approved until: 31 March 2019

    Medicine in short supply/unavailable:

    • DIAFORMIN XR metformin hydrochloride 500mg extended release tablet blister pack - ARTG 120868
    • APO-METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack - ARTG 281211

    Section 19A approval holder:

    Link Medical Products Pty Ltd ABN 73 010 971 516

    Approval holder phone number: 1800 181 060

    Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Yaltormin SR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

    Section 19A approved medicine:

    Yaltormin SR 1000mg (metformin hydrochloride) Prolonged Release Tablets

    Import and supply approved until: 31 March 2019

    Medicine in short supply/unavailable:

    • DIAFORMIN XR 1000 metformin hydrochloride 1000mg extended release tablet blister pack - ARTG 208441
    • DIABEX XR 1000 metformin hydrochloride 1000mg extended release tablet blister pack - ARTG 153699
    • APO-METFORMIN XR 1000 metformin hydrochloride 1000 mg modified release tablet blister pack - ARTG 281210

    Section 19A approval holder:

    Link Medical Products Pty Ltd ABN 73 010 971 516

    Approval holder phone number: 1800 181 060

    Treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. Yaltormin SR may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

    Section 19A approved medicine:

    ILEVRO (nepafenac ophthalmic suspension), 0.3%

    Import and supply approved until: 28 February 2019

    Medicine in short supply/unavailable:

    • ILEVRO nepafenac 0.3% eye drops, suspension, bottle - ARTG 230200

    Section 19A approval holder:

    Novartis Pharmaceuticals Australia Pty Ltd ABN 18 004 244 160

    Approval holder phone number: 02 9805 3433

  • Prevention and treatment of postoperative pain and inflammation associated with cataract surgery

  • Reduction in risk of postoperative macular oedema associated with cataract surgery in patients with non-proliferative diabetic retinopathy
  • Pages